Business, energy, technology, markets and global industry news from Business News Today

biosimilars

PharmaDeviceNews biosimilars
Representative image: Biologic vial and infusion setup for multiple sclerosis care, highlighting Teva Pharmaceutical Industries’ Polpharma Biologics deal for a proposed ocrelizumab biosimilar.
Pharma & Biotech

Teva and Polpharma Biologics sign global ocrelizumab biosimilar licensing deal

Teva Pharmaceutical Industries Ltd. has secured exclusive global commercialization rights to Polpharma Biologics’ proposed biosimilar to Ocrevus ocrelizumab for multiple sclerosis, covering both intravenous and subcutaneous formulations upon regulatory approval. Polpharma Biologics will remain responsible for development and manufacturing, while Teva will handle regulatory submissions and commercialization across major markets including the United States, Europe,

Read More
Representative image: Biopharmaceutical manufacturing facility illustrating Orion Corporation and Shilpa Medicare’s partnership to develop and supply a nivolumab biosimilar for the European oncology market.
Pharma & Biotech

Shilpa Medicare secures Orion for European nivolumab biosimilar commercialization and supply

Discover how Orion and Shilpa Medicare’s nivolumab biosimilar deal could reshape European oncology access, pricing and hospital procurement.

Read More
Representative image of a modern biologics manufacturing facility. Aurobindo Pharma’s TheraNym Biologics launch highlights India’s push into high-capacity CDMO infrastructure, advanced bioreactor manufacturing, and global biologics outsourcing.
Pharma & Biotech

Aurobindo Pharma launches TheraNym as MSD anchor deal strengthens biologics CDMO push

Find out how Aurobindo Pharma’s TheraNym launch could reshape India’s biologics CDMO ambitions and investor sentiment.

Read More
Representative image showing retinal eye care and injectable ophthalmology treatment as Samsung Bioepis expands Europe’s aflibercept biosimilar market with the launch of OPUVIZ for major retinal diseases.
Pharma & Biotech

Can Samsung Bioepis reshape Europe’s retinal disease biosimilar market with OPUVIZ?

Find out how Samsung Bioepis’ OPUVIZ launch could reshape Europe’s aflibercept biosimilar market and ophthalmology access.

Read More
Representative image of biosimilar development and biologics manufacturing for autoimmune disease treatment, highlighting the Polpharma Biologics and Tuteur licensing deal to expand affordable therapy access across Latin America.
Pharma & Biotech

Can Polpharma Biologics and Tuteur improve access to autoimmune disease biologics in Latin America?

LATAM autoimmune care needs cheaper biologics. Polpharma Biologics and Tuteur are betting a biosimilar deal can shift access.

Read More
Pharma & Biotech

Samsung Bioepis targets Japan’s autoimmune market with ustekinumab biosimilar debut

Japan needs lower biologic costs. Samsung Bioepis’s NIPRO launch tests whether ustekinumab biosimilars can shift autoimmune care.

Read More
Pharma & Biotech

Kexing Biopharm leans on IQVIA as biosimilar competition moves from China to global markets

Biosimilars need speed, but regulators still demand proof. IQVIA and Kexing test whether AI can cut friction without cutting evidence.

Read More
Lannett’s Lanexa Biologics enters U.S. insulin market with interchangeable LANGLARA approval
Pharma & Biotech

Could LANGLARA finally crack the high-cost insulin access problem in the United States?

Insulin access needs more than approvals. LANGLARA’s real test is whether payers and pharmacies turn interchangeability into savings.

Read More
Pharma & Biotech

Why Sun Pharma’s $11.75bn Organon acquisition could reshape specialty pharma

Sun Pharma gets global scale with Organon. The harder test is whether women’s health, biosimilars, and debt discipline can move together.

Read More
Representative image of osteoporosis research and denosumab biosimilar treatment, as Samsung Bioepis presents new SB16 subgroup efficacy data at WCO-IOF-ESCEO 2026.
Pharma & Biotech

Obodence at WCO 2026: Samsung Bioepis sharpens the clinical case for SB16 adoption

Samsung Bioepis presented new SB16 subgroup data at WCO 2026. Read what it means for Obodence adoption, biosimilar trust, and osteoporosis care.

Read More